Cystic fibrosis: scheme ELX/TEZ/IVA in children with F508del CFTR allele?

被引：0
|
作者：
Simon, Annika
机构：
来源：
PNEUMOLOGIE | 2023年 / 77卷 / 08期
关键词：
D O I：
10.1055/a-2038-6734
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
    Donaldson, Scott H.
    Pilewski, Joseph M.
    Griese, Matthias
    Cooke, Jon
    Viswanathan, Lakshmi
    Tullis, Elizabeth
    Davies, Jane C.
    Lekstrom-Himes, Julie A.
    Wang, Linda T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) : 214 - 224
  • [2] PHASE 3 EFFICACY AND SAFETY OF THE ELX/TEZ/IVA TRIPLE COMBINATION IN PEOPLE WITH CF HOMOZYGOUS FOR THE F508DEL MUTATION
    Heijerman, H.
    McKone, E.
    Downey, D. G.
    Mall, M.
    Ramsey, B.
    Rowe, S.
    Tullis, E.
    Van Braeckel, E.
    Welter, J.
    Ahluwalia, N.
    Marigowda, G.
    McKee, C.
    Moskowitz, S.
    Simard, C.
    Sosnay, P.
    Waltz, D.
    Xuan, F.
    Zhang, Y.
    Taylor-Cousar, J.
    McCoy, K.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S347 - S347
  • [3] MODELLING SURVIVAL OF PEOPLE WITH CYSTIC FIBROSIS (PWCF) AGED ≥12 YEARS HOMOZYGOUS FOR THE F508DEL MUTATION TREATED WITH IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND IVACAFTOR (IVA/TEZ/ELX)
    Vega-Hernandez, G.
    MacGregor, G.
    Lopez, A.
    Daly, C.
    Rubin, J. L.
    VALUE IN HEALTH, 2021, 24 : S218 - S218
  • [4] PHASE 3 EFFICACY AND SAFETY OF THE ELX/TEZ/IVA TRIPLE COMBINATION IN PEOPLE WITH CF AND F508DEL/MINIMAL FUNCTION GENOTYPES
    Jain, R.
    Mall, M.
    Drevinek, P.
    Lands, L.
    McKone, E.
    Polineni, D.
    Ramsey, B.
    Taylor-Cousar, J.
    Tullis, E.
    Vermeulen, F.
    Marigowda, G.
    McKee, C.
    Moskowitz, S.
    Nair, N.
    Savage, J.
    Simard, C.
    Tian, S.
    Waltz, D.
    Xuan, F.
    Rowe, S.
    Middleton, P.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S346 - S347
  • [5] MOLECULAR CHARACTERIZATION OF F508DEL/F508DEL FERRET MODEL OF CYSTIC FIBROSIS
    Evans, T.
    Sun, X.
    Yan, Z.
    Iiang, B.
    Yi, Y.
    Yang, Y.
    Feng, Z.
    Park, S.
    Qi, L.
    Engelhardt, J.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S323 - S323
  • [6] Long-term safety and efficacy of elexacaftor/ tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis (CF) and at least one F508del allele: An openlabel, 192-week extension study
    Selvadurai, H.
    Polineni, D.
    Daines, C.
    Tullis, E.
    Costa, S.
    Linnemann, R.
    Mall, M.
    McKone, E.
    Quon, B.
    Ringshausen, F.
    Taylor-Cousar, J.
    Withers, N.
    Ahluwalia, N.
    Chin, A.
    Chu, C.
    Jennings, M.
    Tan, Y.
    Waltz, D.
    Weinstock, T.
    Ramsey, B.
    Griese, M.
    RESPIROLOGY, 2024, 29 : 167 - 167
  • [7] Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
    Sermet-Gaudelus, Isabelle
    Clancy, John P.
    Nichols, David P.
    Nick, Jerry A.
    De Boeck, Kris
    Solomon, George M.
    Mall, Marcus A.
    Bolognese, James
    Bouisset, Florilene
    den Hollander, Wilhelmina
    Paquette-Lamontagne, Nicolas
    Tomkinson, Nigel
    Henig, Noreen
    Elborn, J. Stuart
    Rowe, Steven M.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (04) : 536 - 542
  • [8] MODELLING SURVIVAL OF PEOPLE WITH CYSTIC FIBROSIS (PWCF) AGED ≥12 YEARS HETEROZYGOUS FOR THE F508DEL MUTATION WITH A MINIMAL FUNCTION MUTATION TREATED WITH IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND IVACAFTOR (IVA/TEZ/ELX)
    Vega-Hernandez, G.
    MacGregor, G.
    Lopez, A.
    Daly, C.
    Rubin, J. L.
    VALUE IN HEALTH, 2021, 24 : S213 - S213
  • [9] Decoding F508del Misfolding in Cystic Fibrosis
    Wang, Xiaodong Robert
    Li, Chenglong
    BIOMOLECULES, 2014, 4 (02): : 498 - 509
  • [10] EFFECTS OF LUMACAFTOR/IVACAFTOR IN CYSTIC FIBROSIS PATIENTS HOMOZYGOUS FOR F508DEL CFTR MUTATION
    Melotti, P.
    Tridello, G.
    Pintani, E.
    Meneghelli, I
    Volpi, S.
    Spinelli, E.
    D'Orazio, C.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 242 - 242
12345